Nutriband Provides An Update On Its Aversa Fentanyl Product Development Program As It Aims To Complete Scale-up Of The Commercial Manufacturing Process And Move Towards The Single Phase 1 Human Abuse Potential Study Before FDA Application Filing
Portfolio Pulse from Benzinga Newsdesk
Nutriband has provided an update on its Aversa Fentanyl product development program, aiming to complete the scale-up of the commercial manufacturing process and move towards a single Phase 1 human abuse potential study before filing an FDA application.
June 20, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nutriband is progressing with its Aversa Fentanyl product, focusing on scaling up commercial manufacturing and preparing for a Phase 1 human abuse potential study before filing for FDA approval.
The update indicates significant progress in the development of Aversa Fentanyl, which is a positive signal for investors. Successfully scaling up manufacturing and moving towards a Phase 1 study are critical steps before FDA approval, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100